01—Abstract
Summary
Summary of the 10-Q filed August 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported a decrease in net revenue for the third quarter and the first nine months of fiscal year 2024 compared to the prior year periods, driven by decreased product sales in its Life Sciences and Applied Markets, and Diagnostics and Genomics segments.
This decline was partially offset by revenue growth in the Agilent CrossLab segment. Despite lower revenues, the company saw a significant increase in net income for the quarter, primarily due to strong operational performance and a reduction in costs compared to the prior year, which was impacted by substantial asset impairment charges. Agilent also announced a significant acquisition of BIOVECTRA for $925 milliona, expected to close before calendar year 2025, signaling a strategic move to expand its capabilities.
The company is actively managing its cost structure through restructuring initiatives, including headcount reductions, which contributed to improved operating margins year-over-year. Agilent continues to return capital to shareholders through dividends and a robust share repurchase program, with approximately $709 millionb remaining authorization under its 2023 repurchase program and a new $2.0 billion program set to begin in August 2024. Despite ongoing market challenges and customer capital expenditure pressures, particularly in China, Agilent remains optimistic about long-term growth prospects in its key end markets.
02—Key points
Key Highlights
- Net revenue declined by 6% for the third quarter and 7% for the first nine months of fiscal year 2024 compared to the prior year.
- Net income for the three months ended July 31, 2024, significantly increased to $282 million from $111 million in the prior year period.
- Announced agreement to acquire BIOVECTRA for $925 million, a strategic move expected to enhance its contract development and manufacturing capabilities.
- The company implemented significant restructuring costs totaling $67 million in the third quarter of fiscal year 2024, primarily related to workforce reductions.
- Operating margin improved substantially year-over-year, increasing by 13 percentage points in the third quarter, driven by cost management and reduced prior-year impairment charges.
- Agilent continued to return capital to shareholders, paying $68 million in dividends and repurchasing $585 million of its common stock in the third quarter.
- Despite revenue declines in Life Sciences and Applied Markets and Diagnostics and Genomics segments, the Agilent CrossLab segment showed revenue growth of 4% in the quarter.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Agilent Technologies, Inc. kept $0.18.
- Revenue$1.58B100.0%
- Cost of revenue−$723.0M45.8%
- Gross profit$855.0M54.2%
- Operating costs−$522.0M33.1%
- Operating income$333.0M21.1%
- Interest, other & tax−$51.0M3.2%
- Net income$282.0M17.9%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed August 30, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $1.58B$1.67B | −5.6% |
| Cost of Revenue | $723.00M$1.01B | −28.7% |
| Gross Profit | $855.00M$658.00M | +29.9% |
| R&D Expenses | $127.00M$118.00M | +7.6% |
| SG&A Expenses | $395.00M$407.00M | −2.9% |
| Operating Expenses | $1.25B$1.54B | −19.1% |
| Operating Income | $333.00M$133.00M | +150.4% |
| Interest Expense | $22.00M$24.00M | −8.3% |
| Net Income | $282.00M$111.00M | +154.1% |
| EPS (Basic) | $0.97$0.38 | +155.3% |
| EPS (Diluted) | $0.97$0.38 | +155.3% |
| Shares Outstanding (Basic) | 290.00M294.00M | −1.4% |
| Shares Outstanding (Diluted) | 291.00M295.00M | −1.4% |
05—Questions
Frequently Asked Questions
What were the primary drivers of Agilent's revenue performance in the third quarter of fiscal year 2024?
Agilent experienced a 6% decrease in net revenue for the third quarter of fiscal year 2024, primarily driven by lower product sales in the Life Sciences and Applied Markets segment (down 8%) and the Diagnostics and Genomics segment (down 9%). This was partially offset by a 4% increase in revenue from the Agilent CrossLab segment. The company cited customer capital expenditure pressures and a challenging market environment, particularly in China, as contributing factors to the revenue decline.
How did Agilent's profitability change in the third quarter of fiscal year 2024 compared to the prior year?
Profitability saw a significant improvement. Net income rose to $282 million, a substantial increase from $111 million in the same period last year. This improvement was driven by a strong increase in operating income, which grew by 151% to $333 million. The improved operating margin of 21.1% (up 13 percentage points) reflects the positive impact of cost management initiatives, including restructuring charges, and a significant reduction in prior-year asset impairment charges related to the Resolution Bioscience business.
What is the strategic rationale behind the announced acquisition of BIOVECTRA?
Agilent announced the agreement to acquire BIOVECTRA, a specialized contract development and manufacturing organization (CDMO), for $925 million. This acquisition is expected to significantly enhance Agilent's capabilities in serving the biopharmaceutical market, particularly in areas like oligonucleotide manufacturing for therapeutics. It represents a strategic move to expand its offerings in high-growth areas within the life sciences sector.
What is the company doing to manage costs and improve efficiency?
Agilent is actively managing its cost structure through various initiatives. This includes a significant restructuring plan announced in fiscal year 2024, which involves approximately 500 employee reductions (about 3% of the global workforce), resulting in $67 million in restructuring charges for the quarter. These actions are aimed at reducing annual costs and improving operational efficiency. The company also benefited from lower shipping costs, reduced amortization expenses, and targeted pricing strategies.
06—Continue